IDEXX Laboratories (IDXX) — Company Research
Last Updated: 23 June 2026
IDEXX Laboratories (Nasdaq: IDXX) is the global leader in veterinary diagnostics, supplying in-clinic analysers, consumables, reference-laboratory testing and practice-management software to companion-animal vets, plus water-microbiology and livestock/poultry/dairy testing. The company runs a razor-and-blade model with deep recurring revenue and an estimated 60–65% share of North American in-clinic diagnostics. FY2025 revenue was $4.30 billion (+10%) with GAAP EPS up 23% to $13.08. The shares have pulled back meaningfully from a 52-week high near $770 to the mid-$500s, leaving a high-quality compounder trading at a premium but more reasonable multiple. This report uses only primary-source company filings.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | IDEXX Laboratories, Inc. |
| Ticker | IDXX (Nasdaq) |
| Sector | Healthcare — Veterinary Diagnostics |
| CEO | Michael Erickson (President & CEO since 12 May 2026; Jay Mazelsky is Executive Chair) |
| Headquarters | Westbrook, Maine, USA |
| Employees | ~11,000 |
| Market cap | ~$43.1bn (June 2026) |
| Revenue (FY2025) | $4,303.7M ($4.30bn) |
| Net income (FY2025) | $1,059.5M |
| GAAP diluted EPS (FY2025) | $13.08 |
| Dividend | None (no dividend; capital returned via buybacks) |
2. Bull / Bear Case
Bull Case
- Dominant, durable franchise: ~60–65% share of North American in-clinic diagnostics with a large, growing installed base of premium analysers driving recurring consumable revenue.
- Recurring, high-margin revenue: CAG Diagnostics recurring revenue is the engine, supporting gross margins above 60% and consistent double-digit EPS growth.
- Innovation cycle: the IDEXX inVue Dx cellular analyser and IDEXX Cancer Dx (lymphoma plus new canine mast cell tumour testing) extend the menu into high-value oncology and cytology.
- Strong cash generation: FY2025 operating cash flow of $1.18bn and ~$1.06bn free cash flow fund buybacks and reinvestment without a dividend drag.
Bear Case
- Premium valuation: even after the pull-back the stock trades around 42x trailing earnings and ~29x EV/EBITDA, leaving little room for disappointment.
- Soft vet-visit volumes: US clinical visit volumes have been pressured, making organic growth more reliant on price and new instruments than on underlying traffic.
- Intensifying competition: Mars (Antech, Heska/Element) and Zoetis (Vetscan) are building integrated, sometimes lower-priced diagnostics alternatives.
- Leadership transition: a new CEO took over in May 2026 amid a multi-year succession, adding execution uncertainty at the top.
3. Segment Breakdown
IDEXX reports three segments. Figures below are FY2025 segment revenue and share of the $4.30bn total; CAG (Companion Animal Group) dominates the mix.
| Segment | % of revenue (FY2025) | What it is |
|---|---|---|
| Companion Animal Group (CAG) | ~92% ($3,953M) | In-clinic analysers and consumables, reference-lab testing, rapid assays and veterinary software for companion animals. |
| Water | ~5% ($201M) | Microbiology testing products for detecting contaminants in drinking and environmental water. |
| Livestock, Poultry & Dairy (LPD) | ~3% ($132M) | Diagnostic tests for production animals and herd-health management. |
| Other | ~0.4% ($17M) | Out-licensing arrangements and smaller product lines. |
4. Business Model
IDEXX operates a razor-and-blade model centred on the veterinary clinic. It places premium diagnostic instruments into vet practices, then earns the majority of its revenue from the recurring consumables, test cartridges, reference-laboratory services and software subscriptions those instruments and practices consume every day.
How it makes money: the company's most important metric is CAG Diagnostics recurring revenue — the steady stream of consumables and lab tests tied to the installed base. New instrument placements (a record was set in Q4 2025) seed future recurring revenue, while software and rapid assays deepen the relationship with each clinic.
Unit economics and moat: the moat comes from a vast captive installed base, proprietary test menus, an integrated reference-lab network, switching costs created by software and workflow integration, and scale in R&D. These let IDEXX sustain 60%+ gross margins, ~31% operating margins and pricing power, reinvesting cash flow into new diagnostics and buybacks rather than a dividend.
5. Financial Health
The annual table covers FY2021–FY2025; the quarterly table shows the most recent five quarters, most recent first. IDEXX reports a single GAAP diluted EPS and guides on a "comparable" growth basis only, so the Adjusted EPS column mirrors GAAP EPS.
| Fiscal Year | Revenue ($M) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Total debt (YE, $M) |
|---|---|---|---|---|---|---|
| 2021 | $3,215M | — | $8.60 | $8.60 | $0.00 | — |
| 2022 | $3,367M | +4.7% | $8.03 | $8.03 | $0.00 | — |
| 2023 | $3,661M | +8.7% | $9.90 | $9.90 | $0.00 | $698M |
| 2024 | $3,898M | +6.5% | $10.67 | $10.67 | $0.00 | $618M |
| 2025 | $4,304M | +10.4% | $13.08 | $13.08 | $0.00 | $450M |
Total debt shown is year-end current plus long-term debt per the consolidated balance sheet. IDEXX pays no dividend; FY2025 EPS growth included roughly a 7-point benefit from comparison with the prior year's discrete litigation accrual.
| Quarter | Revenue ($M) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | $1,140.8M | $3.47 | $3.47 |
| Q4 2025 | $1,091M | $3.08 | $3.08 |
| Q3 2025 | $1,105M | $3.40 | $3.40 |
| Q2 2025 | $1,109M | $3.63 | $3.63 |
| Q1 2025 | $999M | $2.97 | $2.97 |
| FY2025 total | $4,304M | $13.08 | $13.08 |
FY2025 operating cash flow was $1,181.8M and free cash flow ~$1,057M (operating CF less capex of $124.7M). The company carries modest leverage, ending FY2025 with total debt of ~$450M against $180M of cash. See Live Charts for current price action.
6. Valuation
Raw metrics, June 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$43.1bn (≈78.9M shares × ~$545.73, 22 Jun 2026) |
| Enterprise value | ~$43.3bn (market cap $43.1bn + total debt $0.45bn − cash $0.18bn, per FY2025 balance sheet 31 Dec 2025) |
| Trailing P/E (GAAP) | ~41.7x (price $545.73 / FY2025 GAAP diluted EPS $13.08) |
| P/E (forward) | ~37.2x (price $545.73 / FY2026 EPS guidance midpoint $14.68) |
| P/S (TTM) | ~9.7x (market cap $43.1bn / TTM revenue $4.45bn) |
| EV/EBITDA (TTM) | ~28.9x (EV $43.3bn / FY2025 EBITDA ~$1.50bn; EBITDA = operating income $1,360M + D&A ~$140M) |
| P/FCF | ~40.7x (market cap $43.1bn / FY2025 FCF $1.06bn; FCF = operating CF $1,181.8M − capex $124.7M) |
| 52-week high | $769.98 |
| 52-week low | $506.91 |
| Short interest (% of float) | Low single-digit; not separately reported this settlement — verify at Nasdaq / Finviz |
| Days to cover | n/a — see Nasdaq short-interest page |
7. What They're Building
IDEXX's innovation agenda is anchored on expanding its diagnostic menu and instrument platform. The IDEXX inVue Dx cellular analyser saw record placements in late 2025, with FNA (fine-needle aspirate) cytology added in Q4 2025 and broad availability expanding through 2026. The IDEXX Cancer Dx panel, which launched for canine lymphoma, is being extended to canine mast cell tumour detection from mid-2026 in North America — together addressing more than one-third of canine cancer cases. The company continues to invest in reference-laboratory capabilities, rapid assays, AI-enabled diagnostic interpretation and veterinary software, reinforcing the recurring-revenue flywheel that links new instruments to long-tail consumable and lab demand.
8. Competitive Landscape
IDEXX is the clear leader in veterinary diagnostics, but faces well-capitalised integrated rivals. Mars Petcare (Antech reference labs, plus Heska/Element analysers acquired in 2023) and Zoetis (Vetscan point-of-care) are the most direct competitors, with Thermo Fisher and bioMérieux active in broader diagnostics.
| Peer | Market cap (Jun 2026) | Key 2025 metric |
|---|---|---|
| Zoetis (ZTS) | ~$49.6bn | Animal-health leader; Vetscan point-of-care diagnostics is the closest public-company rival |
| Thermo Fisher Scientific (TMO) | ~$184bn | Broad diagnostics & life-sciences; lab instruments and reagents |
| Antech Diagnostics (Mars, private) | n/a — private | Largest US reference-lab competitor via VCA network and Heska/Element analysers |
9. Leadership & Ownership
IDEXX is led by President & CEO Michael Erickson, who took the role on 12 May 2026; long-serving CEO Jay Mazelsky moved to Executive Chair and intends to retire after the May 2027 annual meeting. There has been no material open-market insider buying or selling in 2026 — activity has been limited to routine equity-compensation grants and vesting.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Lawrence D. Kingsley (Director) | 07 May 2026 | RSU vesting | 339 | — | — | Comp award |
| Karen Peacock (Director) | 2026 | DSU / option grant | 234 DSUs / 525 opt | — | — | Comp award |
| Michael Erickson (then EVP, now CEO) | 12 Feb 2026 | Option grant | 13,667 options | — | — | Comp award |
10. Key Risks
- Premium valuation (Financial): at ~42x earnings the shares price in continued execution; multiple compression is the largest downside risk.
- Soft vet-visit volumes (Macro): pressured US clinical visit traffic makes growth more dependent on price and new instruments.
- Competitive intensity (Operational): Mars/Antech and Zoetis offer integrated, sometimes cheaper diagnostics alternatives.
- New-instrument adoption (Operational): returns depend on continued inVue Dx and Cancer Dx placement and utilisation ramps.
- FX exposure (Macro): international revenue exposes results to currency swings.
- Leadership transition (Operational): a new CEO from May 2026 introduces execution and strategy-continuity risk.
11. Recent Developments
- 29 Apr 2026 — Q1 FY2026 results beat; guidance raised. Revenue rose 14.3% to $1.14bn and management lifted FY2026 EPS guidance to $14.45–14.90.
- 12 May 2026 — CEO transition. Michael Erickson became President & CEO; Jay Mazelsky transitioned to Executive Chair.
- 02 Feb 2026 — Q4 & FY2025 results. FY revenue $4.30bn (+10%) and GAAP EPS $13.08 (+23%); 2026 guidance introduced.
- 15 Jan 2026 — Cancer Dx expansion. Canine mast cell tumour testing added to the Cancer Dx panel, rolling out mid-2026 in North America.
- Q4 2025 — Record inVue Dx placements. Over 1,900 placements in the quarter and the launch of FNA cytology on the inVue Dx analyser.
12. Key Dates
- Expected Aug 2026 — Q2 FY2026 earnings (early August, per prior-year pattern)
- Expected Nov 2026 — Q3 FY2026 earnings
- Expected Feb 2027 — Q4 & full-year 2026 results
Track macro catalysts on the Economic Calendar and discuss this name in the Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. IDEXX Laboratories is the dominant veterinary-diagnostics franchise, running a razor-and-blade model where premium analysers seed high-margin recurring consumable and reference-lab revenue, with the Companion Animal Group making up about 92% of sales. FY2025 revenue was $4.30bn (+10%) with GAAP EPS of $13.08 (+23%); after a Q1 FY2026 beat, management raised FY2026 EPS guidance to $14.45–14.90. The growth engine is CAG Diagnostics recurring revenue, extended by new instruments (inVue Dx) and an expanding oncology menu (Cancer Dx).
What would confirm or break it. Sustained double-digit recurring-revenue growth, strong new-instrument placements and a successful Cancer Dx rollout would confirm the thesis. It would break if the premium ~42x valuation compresses, US vet-visit volumes stay soft, or integrated competitors (Mars/Antech, Zoetis) erode IDEXX’s diagnostics share.
Watchpoints
- ConfirmsQ2 FY2026 earnings (41 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Dominant, durable franchise:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Premium valuation (Financial):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 23 Jun 2026.